Seeking Alpha

GSK (GSK) begins Phase III trials of its mepolizumab antibody treatment for severe refractory...

GSK (GSK) begins Phase III trials of its mepolizumab antibody treatment for severe refractory asthma after an earlier study showed that it almost halved the number of attacks in patients. Around 4% of asthma sufferers experience the severe form of the disease.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector